10 February 2022>: Clinical Research
A Single-Center, Randomized, Double-Blind Study of 94 Patients Undergoing Surgery for Cerebral Glioma to Compare Postoperative Thromboprophylaxis with and without Rivaroxaban
Zi-Yan Wang 1ABC , You-Dong Wan 2CDEF , Xian-Zhi Liu 1EFG , Hao Wang 1AD , Guang-Yi Jiang 1ABF , Bo Yang 1ABCDEFG*DOI: 10.12659/MSM.934341
Med Sci Monit 2022; 28:e934341
Table 1 Baseline characteristics of participants with rivaroxaban and placebo.
Parameter | Rivaroxaban (n=47) | Placebo (n=47) | P value |
---|---|---|---|
Age (year) (mean±SD) | 53.87±7.66 | 54.10±6.46 | 0.87 |
Sex (Female( | 29 (61.7%) | 26 (55.3%) | 0.53 |
BMI (mean±SD) | 22.04±2.48 | 22.04±3.02 | 0.62 |
Laboratory tests | 0.31 | ||
Platelets (×10/L) | 177.57±43.02 | 171.06±37.59 | 0.43 |
Hemoglobin (g/L) | 150.09±12.77 | 149.38±9.02 | 0.76 |
Medical history | 8 (17.0%) | 7 (14.9%) | 0.77 |
Diabetes | 3 (6.4%) | 2 (4.3%) | |
Coronary artery disease | 1 (2.1%) | 2 (4.3%) | |
Venous thromboembolism | 1 (2.1%) | 0 | |
Stroke | 1 (2.1%) | 4 (8.5%) | |
Hypertension | 5 (10.6%) | 2 (4.3%) | |
WHO Glioma grade | |||
I, II | 11 (23.4%) | 14 (29.8%) | 0.48 |
III, IV | 36 (76.6%) | 33 (70.2%) | 0.48 |
Histological type | |||
Oligodendroglioma | 2 (4.3%) | 4 (8.5%) | |
Astrocytoma | 5 (10.6%) | 6 (12.8%) | |
Mixed glioma | 4 (8.5%) | 4 (8.5%) | |
Anaplastic glioma | 10 (21.3%) | 11 (23.4%) | |
Glioblastoma | 23 (48.9%) | 18 (38.3%) | |
Other malignant glioma | 3 (6.4%) | 4 (8.5%) | |
SD – standard deviation; BMI – body mass index. |